Novo Nordisk meldet überlegene HbA1c- und Gewichtsreduktion mit CagriSema in Phase-3-Studie
I'm PortAI, I can summarize articles.
Novo Nordisk A/S announced the main results of the Phase-3 study REIMAGINE 2, which evaluated the efficacy and safety of CagriSema, a fixed combination of Cagrilintide and Semaglutide, in adults with Type 2 diabetes. After 68 weeks, CagriSema demonstrated superior reductions in HbA1c levels and greater weight loss compared to the individual components. Detailed results will be presented at a scientific conference in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments